Events
EASL – International Liver Congress 2021
23–26 June 2021
Digital congress
ENYO Pharma will be present from the 23th to the 26th of June 2021 at the digital EASL International Liver Congress with a first poster “A phase 2 study testing FXR agonist Vonafexor in treatment naive patients with chronic hepatitis B (CHB): preliminary week 16 results” (EASL-ICL 2021 Abstract No. 2844) in the Hepatitis B/D Therapy Session:
And a second poster “Farnesoid X receptor alpha ligands inhibit in vitro HDV replication and virion secretion and infectivity”
HBV-TAG 2021 Conference (Sponsorship)
11-12 June 2021
Virtual Conference
ENYO Pharma has sponsored the 2021 Inaugural Virtual Hepatitis B – Therapeutic Agents Conference.
www.hbv-tag.org
“The primary objective of the Virtual HBV-TAG Conference is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with HBV. The aim of the HBV-TAG conference is to bring together key opinion leaders from the teams of clinicians that care for patients with HBV (hepatologists and gastroenterologists) and pharmaceutical industry representatives to discuss optimized trial design,
Chronic Hepatitis B Drug Development Summit
5-6 May, 2021
Pietro Scalfaro, our CMO, will present clinical results of our lead compound Vonafexor at the Chronic Hepatitis B Drug Development Summit : “Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B”.
This Summit is the first-ever dedicated digital industry forum dedicated exclusively to the frontier of drug development in Chronic HBV. The two-day program explores the full spectrum of antiviral & immunomodulatory agents being investigated to achieve a functional cure in chronic HBV infection &
Talk at the Annual Conference of Autophagy DRIVE Consortium
Benoît de Chassey gave a talk entitled: “From Virus-Host Interactomes To Drug Discovery” at the Annual Conference of Autophagy DRIVE Consortium (Driving next generation autophagy researchers towards translation) coordinated by Pr Fulvio Reggiori.
Immunotherapies & Innovations for Infectious Diseases Congress 2020
December 9-10, 2020
Digital Edition
ENYO will attend the 4th edition of I4ID congress. The purpose of this two-day congress is to foster interactions between pharmaceutical industries, research labs, service providers, technology developers, and clinicians, thereby contributing to the development of innovative strategies against infectious diseases in a multidisciplinary approach.
Latest Press Release 